Big Picture Vienna
БЪЛГАРСКИЯТ
ДЕРМАТОЛОГИЧЕН
ПОРТАЛ


 

EADVirtual

Начало » Важни събития » EADVirtual
EADVirtual

Уважаеми колеги,

В тази трудна за всички ни година, провеждането на конгреси се оказа изключително трудна задача, изискваща изобретателност и много компромиси. Епидемичната ситуация наложи отмяната и отлагането на множество събития или провеждането им в редуциран вид, онлайн или в различни хибридни форми, съчетаващи присъствена и дистанционна форма. Тазгодишния конгрес на ЕАДВ ще се проведе онлайн, което с всички свои недостатъци, все пак ще ни позволи да получим своя достъп до най-новите постижения на дерматологията и да повишим своята квалификация. В програмата тази година с включени изключително интересни лекции, свързани с новостите в дерматологията и с предизвикателствата, пред които ни изправя епидемията от корона вирус. Имаме удоволствието да представим на Вашето внимание списък с подбрани за Вас лекции и кратки разяснения, които да Ви помогнат да подредите своите приоритети при избора на сесии, които да проследявате по време на конференцията. Имам също така и удоволствието да представим на Вашето внимание, темите на лекциите на българските лектори, които ще представят страната ни на конгреса на ЕАДВ шпрез тази година:

Skin lesions induced by Covid 19: how to make the diagnosis? - Prof. Nikolai Tsankov

Occupational dermatitis. - Assoc. Prof. Jana Kazandjieva

PRP and mesotherapy: Do they work? - Assoc. Prof. Razvigor Darlenski

Laser-assisted drug delivery in refractory vitiligo - Prof. Miroslava Kadurina

Isotretinoin: The dose matters. - Prof. Snejina Vassileva

Представяме на Вашето внимание някои от по-интересните лекции от виртуалния конгрес на ЕАДВ:

 
SHIFTING THE PERFUME PARADIGM: A NOVEL ALLERGEN-DEPLETED FRAGRANCE COMPOSITION PROVIDES ANTI-INFLAMMATORY EFFECTS IN VITRO AND SOOTHES XEROTIC SKIN IN VIVO TO ENHANCE PATIENTS' TREATMENT ADHERENCE
The long standing paradigm of fragranced moisturisers considered as allergenic risk in the treatment of xerotic dermatoses may soon become obsolete.

SAFETY AND EFFICACY OF AN ORALLY ADMINISTERED, SINGLE STRAIN COMMENSAL MICROBE IN PSORIASIS AFTER 28 DAYS OF THERAPY: EDP1815
First clinical evidence of modulation of systemic inflammation by an oral, safe, luminally-restricted microbial therapeutic. Currently no licensed drugs are known to treat human disease by this mechanism of action.

PERIANAL WARTS AS A RISK MARKER FOR ANAL HR-HPV DETECTION AND HPV ASSOCIATED DISEASES
The presence of perianal warts is a suitable risk marker for anal HPV 16 detection and anal dysplasia. 

IXEKIZUMAB SHOWS EARLY AND SUSTAINED RESOLUTION OF NAIL PSORIASIS IN PATIENTS WITH PSORIATIC ARTHRITIS AND MODERATE-TO-SEVERE PSORIASIS: 52-WEEK RESULTS FROM A MULTICENTRE, RANDOMISED, OPEN-LABEL, RATER-BLINDED STUDY (SPIRIT-H2H)
Headline summary: In post-hoc analysis IXE maintained complete resolution of nail psoriasis in patients with active PsA and moderate to severe PsO.

INNOVATIVE DIGITAL SOLUTION SUPPORTING SUN PROTECTION AND VITAMIN D SYNTHESIS BY USING SATELLITE-BASED MONITORING OF SOLAR RADIATION
Satellite based monitoring of solar radiation supports sun protection and vitamin D synthesis.

GONORRHEA IN A TERTIARY CARE EUROPEAN HOSPITAL: A 10-YEAR RETROSPECTIVE STUDY OF THE EVOLUTION OF CASES AND DRUG RESISTANCE OF THE ISOLATES
STIs and gonorrhea highly susceptible to antibiotic treatment; however some antibiotics should be avoided.

FACE PROJECT: VALUE OF A NOVEL ARTIFICIAL INTELLIGENCE SOLUTION TO MAKE AT HOME COSMETIC VIRTUAL ANALYSIS IN THE COVID ERA
FACE, AI software could help triage or pre-assess patients ahead of consultations.

EUROPEAN PRURIGO PROJECT: PATIENT PERSPECTIVE ON THERAPEUTIC NEEDS AND SATISFACTION
EUROPEAN PRURIGO PROJECT reports high levels of patient dissatisfaction with therapy and the need for guidelines and new treatments such as biologics in the management of CNPG.

EFFICACY AND SAFETY OF RUXOLITINIB CREAM FOR THE TREATMENT OF ATOPIC DERMATITIS: POOLED ANALYSIS OF TWO PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDIES
ATOPIC DERMATITIS ruxolitinib cream – study shows potential of RUX as an effective and well tolerated topical treatment for AD.

EFFECTIVENESS AND SAFETY OF ZINC OXIDE NANOPARTICLE-COATED SOCKS COMPARED TO UNCOATED SOCKS FOR THE PREVENTION OF UNPLEASANT FOOT ODOUR: A DOUBLE-BLINDED, RANDOMIZED, CONTROLLED TRIAL STUDY
FOOT ODOUR - Zinc oxide nano particle-coated socks prove their efficacy in preventing foot odour.

COVID-19 AND STIS
COVID (ITALY) AND STIs story – the COVID-19 pandemic, despite lockdown and advice on Social/Physical distancing, did not inhibit risky behaviours.

CLINICAL, INSTRUMENTAL AND EX-VIVO EVALUATION OF A PRODUCT CONTAINING 5% LOW MOLECULAR WEIGHT HYALURONIC ACID ASSOCIATED WITH ORGANIC SILICIUM, 0,1% OF PURE RETINOL, PHOSPHOLIPIDS AND POLYSSACHARIDES WITH DUAL ACTION IN THE IMPROVEMENT OF SKIN ELASTICITY, FIRMNESS AND WRINKLES
A product that under study proved to be effective in treating aging signs, with double action, promoting improvement of wrinkles, sagging and loss of skin elasticity.

BIMEKIZUMAB VERSUS USTEKINUMAB EFFICACY ACROSS SUBGROUPS OF PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS: RESULTS FROM THE MULTICENTRE, RANDOMISED, DOUBLE-BLINDED PHASE 3 BE VIVID TRIAL
PSORIASIS - Phase III trial results for UCB Stelara showing robust and durable complete skin clearance in patients with PSO through 52 weeks.

RELATIONSHIP BETWEEN SEBORRHEIC DERMATITIS AND CLIMATE CHANGE
Environmental factors (in Turkey) such as high humidity, high cloud rate and low temperature are important in the emergence of seborrheic dermatitis.

REAL-WORLD EVALUATION OF BIOLOGIC AND NONBIOLOGIC SYSTEMIC PSORIASIS TREATMENT PATTERNS IN SWEDEN
In real world treatment settings in Sweden, results indicate substantial undertreatment of psoriasis patients.

IMPACT OF TARGETING INTERLEUKIN-13 ON STAPHYLOCOCCUS AUREUS COLONISATION: RESULTS FROM A PHASE 3, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL WITH TRALOKINUMAB IN ADULT PATIENTS WITH ATOPIC DERMATITIS
Significant reduction in S. aureus colonisation in lesional skin compared with placebo in adults with moderate to severe AD by neutralisation of IL-13 (Leo Pharma).
THE IMPACT OF COVID-19 IN A LARGE POPULATION OF PSORIATIC PATIENTS UNDERGOING BIOLOGICS
COVID (Italy) - Biologics increase infection risk but protect psoriatic patients from ICU hospitalisation and death


 
« Предишна   Следваща »
Анкета
Как мислите, че трябва да се провеждат научните конференции в условията на настоящата пандемия?
EADV
  

 

© 2016 PRODERMACLUB, всички права запазени